Linvoseltamab Pivotal Data Presented At AACR Reinforce High Response Rate That Deepens Over Time In Patients With Heavily Pre-Treated Multiple Myeloma

Sundar Jagannath

Press/Media

Period	7 Apr 2024 → 8 Apr 2024

Media coverage

117

Media coverage

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	Drugs.com
Country/Territory	United States
Date	8/04/24
URL	ct.moreover.com/?a=53518610920&p=1gw&v=1&x=t0JXI9mJncNqMyLjR27H5A
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented At AACR Reinforce High Response Rate That Deepens Over Time In Patients With Heavily Pre-Treated Multiple Myeloma
Media name/outlet	MENAFN -Press Releases (English)
Country/Territory	Jordan
Date	7/04/24
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	Street Insider
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516809910&p=1gw&v=1&x=lHJ1KuNRK1ao9iysx7WMgA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	BioSpace
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53519710732&p=1gw&v=1&x=z1gkpmbMEBKPHGAwdQaObA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	InvestorsObserver
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516827145&p=1gw&v=1&x=pUTdfYTFrqxcIc4k46J-nw
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	Yahoo! Finance
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516877601&p=1gw&v=1&x=mLxy_x0UJRXSrIaR7YwSWA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	ADVFN UK
Country/Territory	United Kingdom
Date	7/04/24
URL	ct.moreover.com/?a=53516820296&p=1gw&v=1&x=E-dtrf6pUVkk3HMD24ItYA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	Big Country
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517019751&p=1gw&v=1&x=uLbcJn_rbJ61KOj7TaEd5A
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	ADVFN US
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516822106&p=1gw&v=1&x=4I7VBly5xcg1yKx3ukzaXA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	Stockwatch
Country/Territory	Canada
Date	7/04/24
URL	ct.moreover.com/?a=53516822543&p=1gw&v=1&x=PNPFU_snvWE9QLsa1lDGPw
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	Crwe World
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516839001&p=1gw&v=1&x=OZPr5tNH_P5YGqNaHTvPxA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	GlobeNewswire
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516811613&p=1gw&v=1&x=Edeyb-FM9zWIwbq9-yrlDg
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma; Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administrati
Media name/outlet	GlobeNewswire
Country/Territory	United States
Date	7/04/24
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	Fox40 KTXL
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516878576&p=1gw&v=1&x=zUw4RjXzmlB0Ihvbo7Vm4g
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	KSNT TV
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516886152&p=1gw&v=1&x=vdqxp4cFFiOmKY1E-Km3TA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	FOX 59
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516898593&p=1gw&v=1&x=eFp3cMV9vmc_d5P9JWOc8g
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	CW33 NewsFix
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516900354&p=1gw&v=1&x=nx2USmRjplsrnX1cYdgyAg
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	ConchoValleyHomepage.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516903326&p=1gw&v=1&x=YgsLql7XtX3vBLmqOdOO6Q
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	MyPanhandle.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516903328&p=1gw&v=1&x=nueZmxBtZ4UmVxHKkb-FTQ
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WOWK
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516904755&p=1gw&v=1&x=YWFoUqQD_M3ah7sY7tJnQA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WYOU
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516906108&p=1gw&v=1&x=vS10bdhCOzO1tWBpkdrLlQ
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WTVW FOX 7
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516910885&p=1gw&v=1&x=rXQKlSc8IXC8oo35FIbM4Q
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	INFORMNNY.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516913082&p=1gw&v=1&x=gz0lq1EZ6dETDcGJKdZYRw
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WSAV
Country/Territory	Georgia
Date	7/04/24
URL	ct.moreover.com/?a=53516914041&p=1gw&v=1&x=Z49kdfed_Y7uv_5bccx6Fg
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	KGET
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516916336&p=1gw&v=1&x=MDrHBXySDNoUui24D9oz_A
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WBOY
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516916764&p=1gw&v=1&x=IUgyEtuHsm2ql0x8I9_8pQ
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WCBD
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516920498&p=1gw&v=1&x=Mdeu5bfVMl_n9gXYKgX1pg
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	NBC4 Columbus
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516920501&p=1gw&v=1&x=A-pKtfHh7SbZX4FyHbLx7g
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WBTW News13
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516920893&p=1gw&v=1&x=y3Az9clxXinwO-OC6Zs0uA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	FOX 31 News KDVR
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516921541&p=1gw&v=1&x=aCgjiowSpu9OLLzlQt_ufA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	LocalSRY.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516924300&p=1gw&v=1&x=gcjGe2YdecSicvEwz8uj5A
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	KTSM.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516927080&p=1gw&v=1&x=jJMz_amHJQa5Or6OdYOs9w
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WRIC TV
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516928619&p=1gw&v=1&x=yq0MeJVJqq4lweKll8owMg
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	OzarksFirst.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516937135&p=1gw&v=1&x=UhOZSAsr7-c88G-RkRn-_A
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WWLP.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516937313&p=1gw&v=1&x=XxStc_k_lnJ9JFR86qeo3Q
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	KHON 2
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516939396&p=1gw&v=1&x=AgB_BjT05HEeV9xijzYTRA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	Texomashomepage.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516941202&p=1gw&v=1&x=l_xpnZF3uYVTTd_TMpvPjg
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	CBS4Indy
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516947339&p=1gw&v=1&x=rH6QJSRkYcSK3HsvE2PEqw
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WETM 18
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516950662&p=1gw&v=1&x=LlDBMkOoJX04to32hTvF5A
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	KELOLAND TV
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516952561&p=1gw&v=1&x=YwOck63FaYOzKfKfxTPj3g
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WPRI
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516954410&p=1gw&v=1&x=PkWMa2vq7Iv496Pgh1wUXg
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	KXNet.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516955742&p=1gw&v=1&x=XKlmKyfRxl3BvyyENs8rAA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	KRQE
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516956468&p=1gw&v=1&x=wZCumu41dwBK9wAtQWnQ9g
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WDHN
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516956740&p=1gw&v=1&x=-Sm9zVLszP4hcsmzUWGtJA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	CNYHomepage.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516958458&p=1gw&v=1&x=R19aREa4gtgQFkY5K_pjSg
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	MyHighPlains.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516958795&p=1gw&v=1&x=_akVo1hA0gQ6WfaI4lVmgQ
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WRBL-TV
Country/Territory	Georgia
Date	7/04/24
URL	ct.moreover.com/?a=53516960162&p=1gw&v=1&x=MjIcgn_J8ZLaIlzJB8g9Sw
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	KNWA
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516960466&p=1gw&v=1&x=Pgl0VxBiETeBn80cudb9cQ
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WeAreGreenBay.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516962002&p=1gw&v=1&x=bQpXLCeHu97Y5GzDo48YeA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WFXRTV.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516962078&p=1gw&v=1&x=ozX68QN5sefnKFr-0mX4YA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WJHL.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516962998&p=1gw&v=1&x=Q2irHBvM8YzTPdchHwF-8w
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	FOX8 WGHP
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516964659&p=1gw&v=1&x=LkNwgBhHTaLNf0aVhb1Uvw
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WLNS
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516965504&p=1gw&v=1&x=HXkjMZIjzaM8OOAxerK9qA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	Kark.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516965541&p=1gw&v=1&x=4v2uzrUR_eO5G0yky9jJUw
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	MyStateLine.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516966170&p=1gw&v=1&x=MHjKKPSBviWuT7hXME5Hww
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WNTZ
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516966682&p=1gw&v=1&x=r3myJAf9rqiSdvdub-_JTA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	KLFY
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516968148&p=1gw&v=1&x=EpujEbbTSzZYKT60be-Oug
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WNCT
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516969047&p=1gw&v=1&x=2ULiyFPzMbNmcSuieMsHOw
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WREG
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516969135&p=1gw&v=1&x=gSxIH6zt4wwk29b9i-oh4A
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	KTLA
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516971135&p=1gw&v=1&x=WVsEtVkNeYYJxzOYbbiQNg
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	Fox8
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516973038&p=1gw&v=1&x=r2I0c1tIvrQDPP7SjCI1sg
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WJET
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516983969&p=1gw&v=1&x=_HMFsKBAPBPViSfJJ0_Yag
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WKRG
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516985352&p=1gw&v=1&x=9N3DmPs52dKINydR-WZyXg
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	Fox 16
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516987854&p=1gw&v=1&x=z5Kr6ejnz9G81EZkdJdjbg
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	ABC 4
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516987869&p=1gw&v=1&x=qMgycmV1Zs5FQbSJRw2ctg
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WIProud.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516989674&p=1gw&v=1&x=bB7h-GkOHS7L-XRm5PNuZA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WJBF-TV
Country/Territory	Georgia
Date	7/04/24
URL	ct.moreover.com/?a=53516994877&p=1gw&v=1&x=kKJkB4hAAxpBRLRP6Ou7Fw
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WPHL-TV
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516995750&p=1gw&v=1&x=25NwLs5HWxaCnVqQGDaX9Q
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	8 News Now
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516996565&p=1gw&v=1&x=oFtl8MdnLl3v7W_yalIbBw
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	Binghamton Homepage
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516996674&p=1gw&v=1&x=uN4HFuB5pKsxSkVnq9Sxag
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WVNS
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516997206&p=1gw&v=1&x=buEed9_8xj0jbUcCwU7Wag
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WTen.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516997501&p=1gw&v=1&x=RtTKJV228aJBt1PEloYYRg
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	ABC 27
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517000607&p=1gw&v=1&x=eHlDwMBbu9JWcQWriyZReg
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WHNT-TV
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517001151&p=1gw&v=1&x=sx135vhm0WFDP_7juf4Pwg
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WJTV.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517001234&p=1gw&v=1&x=hD9fqc5Ce8Y7kHBDk31_1Q
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	FOX21News.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517002030&p=1gw&v=1&x=by4BmHLDGPRLeqpLS5OHNw
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	KSN
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517002254&p=1gw&v=1&x=FLr_G4q5Q97Yzb0URL3Hag
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WTRF
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517002908&p=1gw&v=1&x=FSsACf0IAlfBvaQlCvs8aQ
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WDTN
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517003493&p=1gw&v=1&x=R56lpliOtDUb332DL8Tuhg
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WIAT TV
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517003531&p=1gw&v=1&x=CiTEmUSx0Xh5x6rx9mESxQ
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WKBN 27 First News
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517012276&p=1gw&v=1&x=N7tYaR4-bFl0JPda6i0Sqg
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	FOX5 San Diego
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517016640&p=1gw&v=1&x=0ljQ89d3Y5LFL7xsGcjVPQ
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WYTV News
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517021471&p=1gw&v=1&x=kQJGZ2V39E0PsW7QiNQNZA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WGNO
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517023116&p=1gw&v=1&x=_vhYhvFKQBr80VZcGwEuJQ
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WSPA.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517028271&p=1gw&v=1&x=GSVJPnA6Sl5vRycDzhG2sQ
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	KFOR.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517034285&p=1gw&v=1&x=gi26fwK9mm9Ize63N0CQKQ
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	KODE TV
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517035370&p=1gw&v=1&x=B183Nkmi-dXJbmWFxUOPwQ
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	Fox 4 WDAF TV
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517036848&p=1gw&v=1&x=G8OEuEd2K9zVEgJVwVa0DA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	YOUR BASIN
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517037821&p=1gw&v=1&x=vXuTElCwa7ruj5AJcJg52w
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WCIA.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517038172&p=1gw&v=1&x=LtDJsV4TtYzFgz-aPu2B6w
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WesternSlopeNow.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517043582&p=1gw&v=1&x=64mPpY3Lw85AlmNRiUhKKw
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	Wavy
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517047487&p=1gw&v=1&x=-1nIdz21a4BMVglUUAt_aQ
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	YourCentralValley.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517059909&p=1gw&v=1&x=qaJYUpmBWRiWBnc20GVH8w
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	My Champlain Valley
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517060954&p=1gw&v=1&x=HH6b0yISUtNDFhIWHJZPgA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	Rochesterfirst.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517061552&p=1gw&v=1&x=s9SmfMYwdrAx435Qs4GcYA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WANE-TV
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517069112&p=1gw&v=1&x=h7PsZZ7Q9DWSdbm0LnoAGQ
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	Myarklamiss.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517079130&p=1gw&v=1&x=dQmCsQEqJJCT-d34xH6v3w
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	WTWO
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517091899&p=1gw&v=1&x=GeFuHRL1b_HyOkZd_ulFQw
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	Valleycentral.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517096594&p=1gw&v=1&x=9Bgl190kpMQ67DoyubuAZA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated
Media name/outlet	L' Observateur
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516831376&p=1gw&v=1&x=PI4O2gJbtIp8jqE9emSjnw
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated
Media name/outlet	MillisMedway - Local Town Pages
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516832545&p=1gw&v=1&x=bzQ6Z4FX1Fee_L1WK3TSxw
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated
Media name/outlet	Luverne Journal
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516835534&p=1gw&v=1&x=nSeZXc1sqdnegreGWgYIqA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated
Media name/outlet	Kenbridge Victoria Dispatch
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516835803&p=1gw&v=1&x=AsFZ4LKb0jO5IJTI4zWW4g
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated
Media name/outlet	BluegrassLive.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516838360&p=1gw&v=1&x=tSYu2DDAHDD-WKaFsr-ZSg
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated
Media name/outlet	TheTidewaterNews.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516843206&p=1gw&v=1&x=YaTuXyofdRUnTqtMwHIrgg
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated
Media name/outlet	Times of San Diego
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516854509&p=1gw&v=1&x=_UaYI9tmPZnkkl4_ZRtDxA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated
Media name/outlet	Leesville Leader
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516866243&p=1gw&v=1&x=qGPVlF-T-WnEiUOgMez2mw
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated
Media name/outlet	Holliston - Local Town Pages
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516867599&p=1gw&v=1&x=6kurZs3urujornxVR8GdzQ
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated...
Media name/outlet	Smithfield Times
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516870646&p=1gw&v=1&x=3EmoxfV0FViHXzorRfjxsw
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated
Media name/outlet	LaGrange Daily News
Country/Territory	Georgia
Date	7/04/24
URL	ct.moreover.com/?a=53516872965&p=1gw&v=1&x=EBYwnDeIu0dfMck8phZxhg
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated
Media name/outlet	Port Arthur News
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516874108&p=1gw&v=1&x=g-SW7T9S3RBF_IcqmIIOAA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated
Media name/outlet	Jessamine Journal
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516880442&p=1gw&v=1&x=aP9l82zZTECWVU6m6cAb7g
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated
Media name/outlet	Tryon Daily Bulletin
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516880774&p=1gw&v=1&x=uhb19Z9ZSYICEk1S-ng0Uw
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated
Media name/outlet	Suffolk News Herald
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516892030&p=1gw&v=1&x=h-1btLsCpDchAtDwrvfMLg
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated
Media name/outlet	Elizabethton.com
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516895226&p=1gw&v=1&x=EnE8338947RO8xMX1eXoTA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated
Media name/outlet	Winchester Sun
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53516896999&p=1gw&v=1&x=F_98yaUSYyxfxnCVfvINqA
Persons	Sundar Jagannath

Title	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Media name/outlet	Regeneron
Country/Territory	United States
Date	7/04/24
URL	ct.moreover.com/?a=53517337247&p=1gw&v=1&x=YlBl7ZIMKl-9VVtSvgc7og
Persons	Sundar Jagannath